Ventricular Arrhythmias and Heart Failure are major causes of morbidity and mortality in the world. There is a growing need for improved therapeutics, and greater recognition that we need much more effective treatments for causes of arrhythmias rather than its symptoms or sequelae. At Elex Biotech we are taking a unique rational approach toward developing new compounds that modulate the function of calcium channels that control the contraction of cardiac muscle. The strength of cardiac muscle contraction is a major factor in ventricular tachycardia and heart failure. Our approach has resulted in new drug candidates or new chemical entities (NCEs) that are potent inhibitors of arrhythmias in animal models. We will initially focus on an orphan/rare disease by targeting a genetically mutated form of a calcium channel that is also involved in the broader arrhythmia market.
